CASP9 and prostate cancer: Additionally, we identified probe sets targeting 27 other genes previously highlighted by the analysis of Gomez Ravetti et al. [5]: NUFIP1, ATP6V1D, UQCRQ, DDX1, WASF1, ATP5C1, COX4I1, SNRK, PPP3CA, LDB2, COX7AP2, LAMTOR2, LDHA, PBX1, CAPRIN2, SLC25A6, SCFD1, DOPEY1, CSPG5, TUBG2, NRXN1, CADPS2, CRYM, FZD5, MAPK1, CASP9, PTN and ICA1. Most of the metafeatures in this cluster that showed a positive correlation with the divergence from control to severe AD were dominated by KLK3 (kallikrein 3), also known as prostate specific antigen, a well-known blood biomarker of prostate cancer [73].